RxDoctor Payments Data

Gregory Hartlage, MD

Cardiovascular Disease · Tallahassee, FLNPI 1174783674

Payments from drug & device makers

$15,420in general payments, 2019–2025

Across 140 payments — averaging $110.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$3K
  • GE HealthCare$3K
  • Edwards Lifesciences$2K
  • Heartflow, Inc.$323
  • AstraZeneca$308
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$3,09829%
  • Travel & lodging$3,37632%
  • Food & beverage$4,01238%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,420 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$170,914
Medicare patients
693
Services billed
1,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban596$503,412
EntrestoSacubitril/Valsartan498$443,156
JardianceEmpagliflozin312$303,088
XareltoRivaroxaban99$100,606
Repatha SureclickEvolocumab104$59,315
FarxigaDapagliflozin Propanediol50$39,868
Icosapent Ethyl82$27,013
VascepaIcosapent Ethyl31$20,456
Atorvastatin Calcium1,192$19,639
Metoprolol Succinate843$16,751
Ranolazine ErRanolazine176$14,640
BrilintaTicagrelor26$13,197
Ezetimibe526$11,613
EdarbiAzilsartan Medoxomil32$10,802
Rosuvastatin Calcium434$6,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$503,412596 claims
NovartisEntresto$68$443,156498 claims
Johnson & JohnsonXarelto$31$100,60699 claims
AstraZenecaFarxiga, Brilinta$308$53,06576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →